About
John P. Butler has served as a member of Akebia Therapeutics' Board of Directors since July 2013 and was appointed President and Chief Executive Officer of Akebia in September 2013. From 2011 to 2013 he was Chief Executive Officer of Inspiration Biopharmaceuticals, Inc., where he led the transactions that resulted in the sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013. From 1997 to 2011 he held various positions at Genzyme Corporation (now Sanofi), most recently as President of the company's rare genetic diseases business and previously leading its renal division, and earlier held sales and marketing positions at Amgen Inc. and Hoffmann-La Roche.
Roles
Akebia Therapeutics, Inc.
Director, President and Chief Executive Officer · Current role
2013–present
Inspiration Biopharmaceuticals, Inc.
Chief Executive Officer · Led the sale of the company's hemophilia assets to Cangene Corporation and Baxter International.
2011-2013
Genzyme Corporation (now Sanofi)
President, rare genetic diseases business · Led the renal division from 2002 to 2010.
1997-2011
External Roles
WaveBreak Therapeutics, Inc.
Board of directors
since 2023
Biotechnology Innovation Organization
Health Section Governing Board member
since 2024
American Kidney Fund
Board of trustees
—
Zynerba Pharmaceuticals, Inc. (now part of Harmony Biosciences)
Board of directors
2018-2023
Relypsa, Inc. (now part of CSL Vifor)
Board of directors
2013-2016
Keryx Biopharmaceuticals, Inc.
Board of directors (Chairman 2016-2017)
2015-2017
Fixed Compensation
FY 2025
All other compensation
$18,220
Total compensation
$5,652,339
Performance Compensation
Data from FY 2025
Cash incentive
Annual cash incentive
$580,973
Stock awards
Also at Akebia Therapeutics, Inc.